Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey

Bone Marrow Transplantation volume 42, pages 99–103 (2008)Cite this article

Abstract

Pancreatic cancer is a frequent cause of cancer-related mortality and has an extremely poor prognosis. To evaluate the efficacy of allogeneic hematopoietic SCT with reduced-intensity conditioning (RICT) against pancreatic cancer, we analyzed the clinical data of 22 patients. After a fludarabine-based conditioning regimen followed by the infusion of PBSCs, all but two achieved engraftment. Complete, partial and minor response was observed in 1, 2 and 2 patients, respectively, with an overall response rate of 23%. Median survival was only 139 days and the major cause of death was tumor progression. Poor performance status before RICT and a lower number of infused CD34-positive cells were associated with shorter survival after RICT. Patients who developed chronic GVHD tended to survive longer than those who did not. These findings support the investigation of a novel treatment strategy to enhance the immunological effect against pancreatic cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.

    Article  CAS  PubMed  Google Scholar 

  2. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19: 916–920.

    Article  CAS  PubMed  Google Scholar 

  3. Bregni M, Ueno NT, Childs R . The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplant 2006; 38: 527–537.

    Article  CAS  PubMed  Google Scholar 

  4. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829–3836.

    Article  CAS  PubMed  Google Scholar 

  5. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234–4236.

    Article  CAS  PubMed  Google Scholar 

  6. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–758.

    Article  CAS  PubMed  Google Scholar 

  7. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.

    Article  CAS  PubMed  Google Scholar 

  8. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212–2217.

    Article  CAS  PubMed  Google Scholar 

  9. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson III AB . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270–3275.

    Article  CAS  PubMed  Google Scholar 

  10. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946–3952.

    Article  CAS  PubMed  Google Scholar 

  11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960–1966.

    Article  CAS  PubMed  Google Scholar 

  12. Kaufman HL, Di Vito Jr J, Horig H . Immunotherapy for pancreatic cancer: current concepts. Hematol Oncol Clin North Am 2002; 16: 159–197, viii.

    Article  PubMed  Google Scholar 

  13. Omuro Y, Matsumoto G, Sasaki T, Tanaka Y, Maeda Y, Sakamaki H et al. Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Bone Marrow Transplant 2003; 31: 943–945.

    Article  CAS  PubMed  Google Scholar 

  14. Takahashi T, Omuro Y, Matsumoto G, Sakamaki H, Maeda Y, Hiruma K et al. Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer. Pancreas 2004; 28: e65–e69.

    Article  PubMed  Google Scholar 

  15. Kanda Y, Komatsu Y, Akahane M, Kojima S, Asano-Mori Y, Tada M et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 2005; 79: 821–827.

    Article  PubMed  Google Scholar 

  16. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.

    Article  CAS  PubMed  Google Scholar 

  17. Heimfeld S . HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 2003; 31: 839–845.

    Article  CAS  PubMed  Google Scholar 

  18. Kim C, Matsumura M, Saijo K, Ohno T . In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998; 47: 90–96.

    Article  CAS  PubMed  Google Scholar 

  19. Trede M, Schwall G, Saeger HD . Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447–458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Geer RJ, Brennan MF . Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68–72; discussion 72–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    Y Kanda & K Oshima

  2. Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan

    Y Omuro & T Sasaki

  3. First Department of Internal Medicine, Kyushu University, Fukuoka, Japan

    E Baba, K Nagafuji & M Harada

  4. Division of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    Y Heike & Y Takaue

  5. Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan

    H Sakamaki

Authors
  1. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Omuro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Nagafuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Heike
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Takaue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Sakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Kanda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanda, Y., Omuro, Y., Baba, E. et al. Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. Bone Marrow Transplant 42, 99–103 (2008). https://doi.org/10.1038/bmt.2008.94

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.94

Keywords

This article is cited by

Search

Advanced search

Quick links